Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.39 |
| ▸ | MTOR | P42345 | 3/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22200568 | 0.90 | ERN1 (0.41) | ERN1PIK3CAMTORBRAFBTK | |
| SCHEMBL22200771 | 0.89 | ERN1 (0.40) | ERN1PIK3CAMTORBRAFBTK | |
| SCHEMBL22200559 | 0.87 | ERN1 (0.40) | ERN1PIK3CAMTORBRAFBTK | |
| SCHEMBL22200582 | 0.87 | PIK3CA (0.43) | ERN1PIK3CAMTORBRAFBTK | |
| SCHEMBL22200575 | 0.86 | ERN1 (0.43) | ERN1PIK3CAMTORBRAFBTK | |
| SCHEMBL22200603 | 0.86 | ERN1 (0.43) | ERN1MTOR | |
| SCHEMBL22200577 | 0.85 | ERN1 (0.49) | ERN1PIK3CAMTORBRAFBTK | |
| SCHEMBL22200572 | 0.85 | ERN1 (0.40) | ERN1PIK3CAMTORBRAFBTK | |
| SCHEMBL25034116 | 0.84 | ERN1 (0.62) | ERN1PIK3CAMTORBRAF | |
| SCHEMBL22200626 | 0.84 | ERN1 (0.41) | ERN1PIK3CAMTORBRAFFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |